MGI(SH:688114) Zhi Tong Cai Jing·2025-07-29 07:25Group 1 - The recent outbreak of Chikungunya virus in Guangdong Province highlights the dual challenges of imported and local transmission, with BGI Genomics' sequencing technology providing critical support for rapid virus tracing [1] - BGI Genomics has deployed nearly 400 SEQ ALL series sequencers across national disease control and customs systems, ready to respond to public health emergencies [1] Group 2 - The T1+ sequencer achieved over 99.9% coverage in sequencing samples from four Chikungunya virus patients, successfully distinguishing between African and Asian strains [2] - The T1+ sequencer can produce Tb-level data within 24 hours and has a rapid sequencing time of 7 hours for SE50 sequencing, significantly enhancing epidemic response efficiency [2] Group 3 - The CycloneSEQ platform, utilizing nanopore technology, provides real-time and portable sequencing capabilities, achieving 100% genome coverage in just 20 minutes, matching traditional high-throughput sequencing results [3] - In 2024, 37 gene sequencers received NMPA approval for clinical testing, with 23 based on BGI Genomics' DNBSEQ technology, representing 62% of the total approved devices in China [3] Group 4 - BGI Genomics has sold over 4,500 gene sequencers globally, capturing approximately 28.2% of the new sales market share, a significant increase of 9.5 percentage points from 2023 [3] - The company is expanding its business beyond core sequencing instruments to include biobanks, cell genomics, and spatial omics, while also exploring applications in judicial and animal disease fields [3] Group 5 - The surge in demand across clinical, agricultural, disease control, and customs sectors, combined with rapid growth in multi-omics business and increasing installation of core sequencers, provides a solid growth driver for BGI Genomics' future performance [4] - As the only company globally with both large-scale commercial short-read (DNBSEQ) and long-read (CycloneSEQ) sequencing products, BGI Genomics is positioned to expand its market share in life science tools and offer diverse solutions for pathogen monitoring and public health safety [4]